ClinicalTrials.gg
CompletedNCT07850765Updated Sep 30, 2026

Real-World Patient and Physician Experience With Semaglutide Across Six Emerging Markets

An observational study in Overweight and Obesity, sponsored by Novo Nordisk A/S. Completed at 6 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-30.

Primary conditionObesityRegistry: OverweightReclassifiedWhy we changed it
Registry
Overweight — the first condition term the registry derived for this study.
ClinicalTrials.gg
Obesity
Why
  1. The study's listed conditions name Obesity, a narrower term within Overweight.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Novo Nordisk A/S · Observational

How we know · 4 judgments

Updated Sep 30, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
1,260
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 210 studies in Obesity by Novo Nordisk A/S — 51 open to participants now, 69 under way, 26 of them phase 3. Obesity · Novo Nordisk A/S.

Enrollment
21st of 41
1,260 · median 1,260
Started
2026
with 49 others
Observational
41 of 210
8 open now
Registered
202nd of 210
by date

Among the 210 studies in Obesity by Novo Nordisk A/S, this one is the 21st largest by enrollment of the 41 observational ones that give a count, is one of 50 that started in 2026, is one of 41 observational ones, and was the 202nd registered.

Obesity

11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

Browse Obesity studies →

Open to participants now

51 of the 210 studies in Obesity by Novo Nordisk A/S are open now, in 12 countries. Recruiting first, the newest first:

46 more — sign in →

By country, each count listing its studies:

All 51 open studies →

Who these studies take

Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 210 studies in Obesity by Novo Nordisk A/S, or all of them as a file.
02

Study summary

The purpose of this study is to assess semaglutide's impact on daily life from participants and physicians experience.

03

Conditions studied

  • Overweight
  • Obesity

Browse trials for

04

In context

Obesity Reclassified

11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

This study's enrollment of 1,260 is above the median of 115 across 2,159 observational studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

Novo Nordisk A/S is the lead sponsor of 1,411 studies on the registry; 108 are open to participants now.

Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.

Compared within Obesity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Overweight. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Participants receiving semaglutide for at least 16 weeks are included for secondary database analysis.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 18 years or older
  • Currently receiving Wegovy for at least 16 weeks, who at initiation of Wegovy had either: of more than or equal to (≥) 27 to less than (\<) 30 kilogram per meter square (kg/m\^2) with at least one weight-related comorbidity and BMI of ≥30 kg/m\^2
  • Not currently involved in a clinical trial for overweight or obesity

Exclusion criteria

Exclusion Criteria:

- This is a secondary database analysis

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

06

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
1,260 participants (actual)
Patient registry
No

Groups and cohorts

  • Obesity PLUS I disease specific programme (DSP)

    Patients included in this study were those who had been diagnosed with overweight or obesity and had been initiated on Wegovy (semaglutide) at least 16 weeks prior to the date the DSP survey was conducted. This study is based on a retrospective analysis of existing physician-reported data collected through the DSP survey.

    Drug: Semaglutide

Interventions

  • This is a retrospective, non-interventional study; therefore, no intervention was administered as part of the study.

07

What researchers measure

Primary outcomes

  1. Change in Food Noise Questionnaire (FNQ) score

    Food noise assessed retrospectively prior to Wegovy initiation and at data capture using the Food Noise Questionnaire (FNQ). The questionnaire evaluates intrusive and persistent food-related thoughts. Each item is scored 0-5, with a total score range of 0-20. Higher scores indicate greater food noise

    Time frame: At data capture (Day 1)

  2. Change in Body Weight

    Change in body weight (kg) from initiation of Wegovy to data capture. Weight measured prior to Wegovy initiation and at data collection.

    Time frame: At data capture (Day 1)

  3. Health-Related Quality of Life Measured by EQ-5D-5L

    Health-related quality of life assessed using the EuroQol 5-Dimension 5-Level (EQ-5D-5L) index score. The EQ-5D-5L consists of 5 items rated on a 5-point Likert scale that ranges from 1 (no problems) to 5 (extreme problems). Higher index scores indicate better health-related quality of life.

    Time frame: At data capture (Day 1)

  4. Health Status Measured by EQ Visual Analogue Scale (EQ-VAS)

    Participant-rated overall health status measured using the EQ-VAS. Scores range from 0 to 100, where higher scores indicate better perceived health.

    Time frame: At data capture (Day 1)

  5. Medication Adherence Measured by Adelphi Adherence Questionnaire (ADAQ)

    Participant-reported adherence to Wegovy treatment assessed using the Adelphi Adherence Questionnaire (ADAQ). The overall adherence summary score ranges from 0 to 4, with lower scores indicating greater medication adherence.

    Time frame: At data capture (Day 1)

  6. Number of Participant Satisfaction With Wegovy

    Participant satisfaction with Wegovy treatment assessed as less than satisfied, satisfied, or more than satisfied according to perceived treatment performance relative to expectations.

    Time frame: At data capture (Day 1)

  7. Change in Body Mass Index (BMI)

    Change in body mass index (kg/m²) from Wegovy initiation to data capture will be reported

    Time frame: At data capture (Day 1)

  8. Percent Change in Body Weight

    Percentage change in body weight between Wegovy initiation and data capture will be reported.

    Time frame: At data capture (Day 1)

  9. Number of Participants with Achievement of Weight-Loss Target

    Participant-reported achievement of the predefined weight-loss goal (Yes/No). Participants may be classified as having reached or exceeded their target weight loss.

    Time frame: At data capture (Day 1)

  10. Number of Participants who Concern About Future Weight Gain

    Number of Participant concern regarding regaining weight after discontinuation of Wegovy treatment will be reported.

    Time frame: At data capture (Day 1)

  11. Impact of Wegovy on Weight-Related Burden

    Degree to which participants were bothered by their weight before starting Wegovy and at data capture after receiving Wegovy.

    Time frame: At data capture (Day 1)

  12. Impact of Wegovy on Daily Life and Health Behaviours

    Changes in work-life impact, cigarette smoking, shisha smoking, and alcohol consumption since initiation of Wegovy.

    Time frame: At data capture (Day 1)

08

Study locations

6 sites
  • Novo Nordisk Investigational Site
    Jerusalem, Israel
  • Novo Nordisk Investigational Site
    Mexico City, Mexico
  • Novo Nordisk Investigational Site
    Riyadh, Saudi Arabia
  • Novo Nordisk Investigational Site
    Pretoria, South Africa
  • Novo Nordisk Investigational Site
    Ankara, Turkey (Türkiye)
  • Novo Nordisk Investigational Site
    Abu Dhabi, United Arab Emirates
09

References and documents

Individual participant data

Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

Data sharing details ↗ · novonordisk-trials.com

No publications or documents are linked to this record.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2026 to primary completion in Aug 2026, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 23, 2026
First posted
Sep 30, 2026
StartActual
Aug 28, 2026
Primary completionActual
Aug 31, 2026
CompletionActual
Aug 31, 2026
Last update
Sep 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Sep 30, 2026
Show all 1 update
  1. Sep 30, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT07850765
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Sep 30, 2026
Start date
Aug 28, 2026
Primary completion
Aug 31, 2026
Completion
Aug 31, 2026
Last update
Sep 30, 2026

Study contacts

Clinical Transparency (dept. 2834)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion